The history of Alzheimer’s research has been filled with setback after setback – in fact nearly every clinical trial has failed – but it is also one marked by perseverance and renewed hope. Advancements in medical imaging have increased our understanding of how the disease strikes, and efforts are underway to develop diagnostics to treat the disease before its onset.
With a growing aging population, how will the disease burden the country’s health care system? The Atlantic will gather leading experts and key stakeholders for a national conversation on what it will take to disrupt Alzheimer’s disease.
Samantha Budd Haeberlein, Vice President, Alzheimer’s Late Stage Clinical Development, Biogen
Elli Kaplan, CEO, Neurotrack
William Klein, Member, Cognitive Neurology and Alzheimer’s Disease Center; Professor of Neurobiology and Neurology Feinberg School of Medicine,
Northwestern University
Johan Luthman, Vice President and Head of Clinical Development, Global Neurology Business Group, Eisai
with Vann Newkirk, The Atlantic
*This speaker participated in a session that was produced by our underwriter and not by The Atlantic's editorial team.
**This session was produced by our underwriter and not The Atlantic's editorial team.
Attendance at our events constitutes acceptance of our Code of Conduct (effective 1/2/2018) and Privacy Policy (effective 1/2/2018).
AtlanticLIVE Copyright (c) 2018 by The Atlantic Monthly Group. All Rights Reserved.